首页 › 基金 › Aisling Capital Management LP › URGN
Aisling Capital Management LP 对 URGN 的持仓历史
UROGEN PHARMA LTD · 医疗保健
Aisling Capital Management LP 在 Q3 2026 的 13F 申报中披露持有 URGN(UROGEN PHARMA LTD)108,000 股,市值约 US$4.4M,约占其申报组合的 1.47%,在其申报持仓中市值排名第 6 位。 Aisling Capital Management LP 最近 4 个申报季度中有 4 个季度披露了 URGN 持仓,最早可追溯至 Q4 2025。
最后更新: 2026-11-13 · 来源: SEC EDGAR Form 13F-HR
Aisling Capital Management LP 对 URGN 的持仓演变
Aisling Capital Management LP 于 Q4 2025 首次披露 URGN 持仓:108,000 股(约 US$2.5M)。 该持仓在 Q3 2026 达到峰值 108,000 股,市值约 US$4.4M。 在 4 次申报中,Aisling Capital Management LP 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 108,000 股、市值约 US$4.4M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q4 2025 | 108.00K | $2.53M | 新进 |
| Q1 2026 | 108.00K | $1.94M | 持有 |
| Q2 2026 | 108.00K | $3.97M | 持有 |
| Q3 2026 | 108.00K | $4.39M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 URGN 与 13F 数据
URGN(UROGEN PHARMA LTD)属于医疗保健行业。我们追踪的基金中还有 45 只申报持有 URGN,申报仓位最大的包括:RTW INVESTMENTS, LP (US$167.2M), Kynam Capital Management, LP (US$89.6M), Jefferies Financial Group Inc. (US$89.4M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 URGN 的基金
- RTW INVESTMENTS, LP 4.54M 股 · $167.22M · Q2 2026
- Kynam Capital Management, LP 2.43M 股 · $89.58M · Q2 2026
- Jefferies Financial Group Inc. 2.20M 股 · $89.37M · Q3 2026
- ACORN CAPITAL ADVISORS, LLC 1.67M 股 · $61.58M · Q2 2026
- Opaleye Management Inc. 1.44M 股 · $52.99M · Q2 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 1.15M 股 · $46.67M · Q3 2026
- MPM BioImpact LLC 933.41K 股 · $34.35M · Q2 2026
- Soleus Capital Management, L.P. 829.81K 股 · $30.54M · Q2 2026
- Boxer Capital Management, LLC 500.00K 股 · $18.40M · Q2 2026
- NEXT CENTURY GROWTH INVESTORS LLC 297.08K 股 · $12.07M · Q3 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 191.31K 股 · $7.04M · Q2 2026
更多关于 Aisling Capital Management LP
常见问题
How long has Aisling Capital Management LP held URGN?
Aisling Capital Management LP has disclosed URGN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Aisling Capital Management LP's current position in URGN?
As of Q3 2026, Aisling Capital Management LP holds 108.00K shares of URGN (UROGEN PHARMA LTD), valued at $4.39M, representing 1.47% of its reported portfolio and ranking #6.
Has Aisling Capital Management LP been buying or selling URGN?
In the latest 13F filing (Q3 2026), Aisling Capital Management LP held unchanged its position in URGN. The position peaked in Q3 2026 at 108.00K shares.
Which other funds hold URGN?
Other major institutional holders of URGN include RTW INVESTMENTS, LP, Kynam Capital Management, LP, Jefferies Financial Group Inc., among 45 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.